Skip to main content

Day: February 7, 2025

Ascentage Pharma Announces Partial Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares

ROCKVILLE, Md. and SUZHOU, China, Feb. 07, 2025 (GLOBE NEWSWIRE) — Ascentage Pharma (Nasdaq: AAPG, HKEX: 6855) announced today that the underwriters of its underwritten U.S. initial public offering (the “Offering”) have partially exercised their over-allotment option to purchase an additional 935,144 American depositary shares (“ADSs”) at the initial public offering price of $17.25 per ADS less underwriting discounts and commissions. Each ADS represents four ordinary shares of Ascentage Pharma. After giving effect to the partial exercise of the over-allotment option, the total number of ADSs sold by Ascentage Pharma in the Offering will increase to 8,260,144 ADSs and the aggregate gross proceeds to Ascentage Pharma will be approximately $142.5 million, before deducting underwriting discounts and commissions and other offering expenses...

Continue reading

Spectral AI Completes Data Analysis for U.S. Burn Pivotal Study

DALLAS, Feb. 07, 2025 (GLOBE NEWSWIRE) — Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”), developer of the AI-driven DeepView® System, which received Breakthrough Device Designation from the U.S. Food and Drug Administration (“FDA”) in 2018 and uses multi-spectral imaging and AI algorithms to predict burn healing potential, today announced the completion of its data analytics for its U.S. Burn Pivotal Study.   One of the largest domestic burn studies ever conducted, the U.S. Burn Pivotal Study is designed to validate the AI-driven algorithm used by the Company’s DeepView® System for its burn indication. Spectral AI’s DeepView® System is a predictive medical device and associated software that assesses the healing potential of burn wounds by combining multispectral imaging with an AI-driven algorithm trained and...

Continue reading

Hampidjan Announces Strategic Investment in Kohinoor Ropes, India

Hampiðjan hf. has signed today, few minutes ago, an agreement to acquire a 75.1% stake in the Indian net and rope manufacturing company Kohinoor Ropes Pvt. Ltd.. Various formalities remain to be completed before the final settlement, but it is expected that it will only take a few weeks as no approval from the competition authorities is required, neither in Iceland nor in India. Due diligence, financial, legal and for ESG has been largely completed. Kohinoor is one of the largest manufacturers of nets and ropes in India with an annual production of approximately 14,300 tons of ropes and nets. The company employs over 700 people and has three locations, two net and rope factories in Selu and a net workshop in Jalna. The company also has an office in Aurangabad. Kohinoor’s operations are in the state of Maharashtra and the offices...

Continue reading

Rio2 Announces Official Start of Construction of Fenix Gold Mine

VANCOUVER, British Columbia, Feb. 07, 2025 (GLOBE NEWSWIRE) — Rio2 Limited (“Rio2” or the “Company”) (TSXV: RIO; OTCQX: RIOFF; BVL: RIO) announces today the celebration of the official start of construction of its Fenix Gold Mine located in the Maricunga Gold Belt of the Atacama Region. The event held on February 6, was attended by the Honorable Aurora Williams Baussa, Minister of Mining; Mr. Mario Silva Álvarez, Deputy Governor of Atacama; Mr. Jorge Riesco Valdivieso, President of SONAMI (Chilean National Mining Society); representatives of the Colla Indigenous Communities; Regional Ministerial Secretaries; representatives of Mining and Industry Guilds and high authorities from InvestChile, CORPROA (The Corporation for the Development of the Atacama Region), and SERNAGEOMIN (National Service of Geology and Mining). The event included...

Continue reading

iAnthus Strengthens Portfolio with $36.5M Sale of Select Arizona Assets to Sonoran Roots

Transaction Supports iAnthus’ Focus on Key Growth Markets While Maintaining Presence in Arizona NEW YORK and TORONTO, Feb. 07, 2025 (GLOBE NEWSWIRE) — iAnthus Capital Holdings, Inc. (“iAnthus” or the “Company”) (CSE: IAN, OTCQB: ITHUF), which owns, operates and partners with regulated cannabis operations across the United States, today announced that certain iAnthus subsidiaries entered into definitive agreements (the “Purchase Agreements”) with a leading Arizona cannabis operator, Pitchfork Enterprises, LLC d/b/a Sonoran Roots and its affiliates (“Sonoran Roots”), to sell three dispensaries and two processing/cultivation facilities in Arizona for aggregate consideration of approximately $36.5 million (the “Transaction”). This strategic transaction is part of the Company’s ongoing efforts to optimize its portfolio, strengthen...

Continue reading

Emergent BioSolutions and Pro Football Legend Emmitt Smith Raise Awareness of Ready to Rescue Campaign Timed to the Big Game in New Orleans

Despite the recently reported national decline in opioid overdose deaths, many U.S. communities, including New Orleans, continue to see an increase in accidental drug-related deaths year over yearThe ‘Lay, Spray, Stay’ opioid overdose educational video featuring Smith and how to use NARCAN® Nasal Spray will appear on local taxi television screens throughout the cityHundreds of NARCAN® Nasal Spray cartons will be given away to people in New Orleans throughout the weekendGAITHERSBURG, Md., Feb. 07, 2025 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) announced today that it is raising awareness of the Ready to Rescue initiative in New Orleans with pro football legend and NARCAN® Nasal Spray spokesperson, Emmitt Smith, as the city welcomes an anticipated 83,000 fans for the Big Game. For the past two years, Smith...

Continue reading

Arq Schedules Q4 & FY 2024 Earnings Conference Call and Upcoming Investor Events

GREENWOOD VILLAGE, Colo., Feb. 07, 2025 (GLOBE NEWSWIRE) — Arq, Inc. (NASDAQ: ARQ) (the “Company” or “Arq”), a producer of activated carbon and other environmentally efficient carbon products for use in purification and sustainable materials, today announced the schedule and conference call details for its fourth quarter and full-year 2024 earnings results, as well as expected participation in upcoming investor conferences. Q4 & FY 2024 Earnings Conference Call The Company expects to release its fourth quarter and full-year 2024 financial results and file its annual Report on Form 10-K for the period ended December 31, 2024 after market close on Wednesday, March 5, 2025. A conference call to discuss the Company’s financial performance will be held on Thursday, March 6, 2025, beginning at 8:30...

Continue reading

ParaZero to Attend IDEX UAE, Leading Defense and Security Exhibition

Tel Aviv, Israel, Feb. 07, 2025 (GLOBE NEWSWIRE) — ParaZero Technologies Ltd. (Nasdaq: PRZO) (the “Company or “ParaZero”), an aerospace company focused on safety systems for commercial unmanned aircrafts and defense Counter UAS systems, is set to attend in IDEX UAE 2025, one of the world’s premier defense and security exhibitions. IDEX UAE, held in Abu Dhabi from February 17-21, 2025, serves as a strategic platform for defense companies to engage with global military. As drone technology continues to evolve, safety and counter-drone solutions are critical for defense and homeland security operations. At IDEX UAE, ParaZero aims to explore new collaborations and market opportunities with defense officials and industry leaders. The company’s presence to show its growing role in shaping the future of drone safety and security...

Continue reading

Neuronetics Announces Pricing of $18 Million Underwritten Public Offering of Common Stock

MALVERN, Pa., Feb. 07, 2025 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM) (the “Company”) today announced that it has priced its previously announced underwritten public offering of its common stock, comprised of 8,000,000 shares of common stock at a public offering price of $2.25 per share, resulting in gross proceeds of approximately $18 million, before deducting underwriting discounts and commissions and other offering expenses payable by the Company. The Company has also granted to the underwriter a 30-day option to purchase up to an additional 1,200,000 shares of common stock at the public offering price per share, less underwriter discounts and commissions. All of the shares in the offering are being sold by the Company. The Company currently intends to use the net proceeds of this offering for general corporate purposes,...

Continue reading

Matinas BioPharma Appoints Evelyn D’An to Board of Directors as Audit Committee Chair

BEDMINSTER, N.J., Feb. 07, 2025 (GLOBE NEWSWIRE) — Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) today announced the appointment of Evelyn D’An to its Board of Directors as an independent director and Chair of the Audit Committee, effective Wednesday, February 5, 2025. Ms. D’An is an experienced board director and financial leader with extensive corporate governance, financial oversight, and accounting experience with a range of both public and private companies, where she has served as Chair of Audit Committees and as a member of various other board committees. Ms. D’An is also a former partner of Ernst & Young, where she spent 18 years serving clients in retail, consumer products, technology, and other sectors. She will serve as Chair of the Matinas Audit Committee and will also serve as a member of the Matinas...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.